Latest news
Living Cell Technologies Receives Health Minister's Approval to Start Leading Edge Live Cell Therapy Clinical Trial in New Zealand for Diabetics
21 October, 2008 - Living Cell Technologies today announced that New Zealand Health Minister, the Honorable David Cunliffe, has approved an application from the company to conduct in New Zealand a Phase I/IIa clinical trial of DiabeCell®, LCT's lead product candidate for the treatment of insulin dependent (Type 1) diabetes.
Click here to download this release in PDF format. (61kb)NOTICE OF ANNUAL GENERAL MEETING
07 October, 2008 - Living Cell Technology gives notice of their Annual General Meeting
to be held at to be held at 1.00 pm on Thursday 6 November 2008 at Stamford Plaza Hotel, Clare Room, 150 North Terrace, Adelaide SA
Click here to download this release in PDF format. (225kb)Annual Report
07 October, 2008 - Living Cell Technology's 2008 Annual Report Living Cell Technologies (LCT) is a global company focused on developing cell-based therapy products to treat life threatening human diseases. The Company has offices in Australia, New Zealand and the USA and is listed on the Australian Stock Exchange as well as the international OTCQX.
Click here to download this release in PDF format. (7.7mb)LCT Informed of Progress for Decision on Diabetes Clinical Trial in New Zealand
June 26, 2008 - Melbourne, Australia and Auckland, New Zealand
Living Cell Technologies Limited (ASX:LCT; OTCQX: LVCLY) today announced that it has received a letter from the New Zealand Minister of Health, the Honorable David Cunliffe, indicating that he has sought independent advice from the National Health Committee (NHC) by 8 August 2008, on LCT’s application to conduct a Phase I/IIa clinical trial with DiabeCell® in New Zealand. View full article.
The NHC is a Ministerial advisory committee that the Minister can seek advice from to complete the statutory requirements of his decision making process on the authorization of LCT’s application. Prior to this stage, LCT had obtained and submitted to the Minister approvals from the Regional Ethics Committee, the Gene Technology Advisory Committee, International Accreditation New Zealand and Medsafe, the regulatory body that approved the manufacture for human use of encapsulated porcine cells (DiabeCell®) under Good Manufacturing Practice standards.
DiabeCell® is the Company’s encapsulated porcine insulin-producing cells currently in development for the treatment of insulin dependent type 1 diabetes without the use of immunosuppressive drugs. Dr Paul Tan, LCT Chief Executive Officer, said, “LCT is pleased with the stated time frame and is committed to assisting the Minister and the NHC with any further information that may be required to ensure that the deadline is met. LCT sees this as a step forwards for its efforts to include New Zealand in the Company’s international clinical trials programme”.
Search our site
DiabeCell®
Natural neo-natal porcine islets encapsulated in an alginate gel and transplanted for the treatment of insulin-dependent diabetes.
More InformationNTCell®
A choroid plexus cell product with the potential to treat neurological diseases such as Parkinson’s disease and stroke.
More InformationFac8Cell
A liver cell product aimed at producing factor 8, a blood clotting agent absent or defective in people suffering haemophilia.
More InformationEncapsulation Technology
LCT’s technology platform involves the implantation of healthy living cells to replace, repair or regenerate diseased or damaged organs.
More InformationVideos
The Advances in Porcine Islet Implants for the Treatment of Type 1 Diabetes Symposium.
More Information